https://assets.capyfin.com/instruments/678fdc13234e27009c5d5bba.png avatar
Exelixis
🇺🇸 NASDAQ:EXEL
View Company
OverviewEarningsDividends
•
Dec 31, 2023

Exelixis Q4 2023 Earnings Report

Exelixis reported strong Q4 2023 results, driven by growth in cabozantinib franchise and advancements in pipeline development.

Key Takeaways

Exelixis announced its Q4 and Fiscal Year 2023 financial results, reporting total revenues of $479.7 million for the quarter and $1.83 billion for the year. The company's GAAP diluted EPS was $0.27 for the quarter and $0.65 for the year, while non-GAAP diluted EPS was $0.33 for the quarter and $0.90 for the year. Exelixis is focused on advancing its cabozantinib franchise and pipeline development.

Total revenues for Q4 2023 were $479.7 million, compared to $423.9 million for the same period in 2022.

Cabozantinib franchise net product revenues in the U.S. were $429.3 million during Q4 2023.

GAAP diluted EPS for Q4 2023 was $0.27, compared to a net loss of $(0.09) per share for the same period in 2022.

Non-GAAP diluted EPS for Q4 2023 was $0.33, compared to a net loss of $(0.03) per share for the same period in 2022.

Total Revenue
$480M
Previous year: $424M
+13.1%
EPS
$0.33
Previous year: -$0.03
-1200.0%
R&D Expenses
$245M
Previous year: $337M
-27.4%
SG&A Expenses
$131M
Previous year: $119M
+10.2%
Tax Expense
$17.5M
Previous year: -$1.25M
-1497.2%
Gross Profit
$458M
Previous year: $408M
+12.2%
Cash and Equivalents
$263M
Previous year: $501M
-47.5%
Free Cash Flow
-$2.56M
Previous year: $72M
-103.6%
Total Assets
$2.94B
Previous year: $3.07B
-4.2%

Exelixis

Exelixis

Exelixis Revenue by Segment

Forward Guidance

Exelixis is maintaining its financial guidance for fiscal year 2024.

Positive Outlook

  • Total revenues are expected to be between $1.825 billion and $1.925 billion.
  • Net product revenues are expected to be between $1.650 billion and $1.750 billion.
  • Cost of goods sold is expected to be 4% - 5% of net product revenues.
  • Research and development expenses are expected to be between $925 million and $975 million.
  • Selling, general and administrative expenses are expected to be between $425 million and $475 million.

Challenges Ahead

  • 2024 financial guidance excludes expenses related to the restructuring plan announced in January 2024.
  • Includes $40 million of non-cash stock-based compensation expense in research and development expenses.
  • Includes $60 million of non-cash stock-based compensation expense in selling, general and administrative expenses.
  • Effective tax rate is expected to be between 20% and 22%.
  • Net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX and COMETRIQ effective on January 1, 2024.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Exelixis